ASX Biotech Share Surges on Development Update

Race Oncology Limited (ASX: RAC)

Race Oncology Limited (ASX: RAC) recently made significant progress with their RC220 bisantrene formulation. On December 5, 2024, they announced the submission of their human ethics and regulatory package to the Bellberry Human Research Ethics Committee (HREC) for approval to begin a Phase 1 clinical trial for RC220 in solid tumour patients. The trial, to be conducted at the Southside Cancer Care Centre in New South Wales, will study RC220 both alone and in combination with the chemotherapy drug doxorubicin. Recruitment is expected to start in Q1 2025, with additional trial sites planned for Hong Kong, South Korea, and other locations. The trial will assess the safety, tolerability, and optimal dosage of RC220, with potential for future Phase 2 studies in multiple regions.????

ChecK Now - https://bit.ly/ASX-Stocks